Technical Analysis for NTRA - Natera, Inc.

Grade Last Price % Change Price Change
B 90.12 0.67% 0.60
NTRA closed up 0.67 percent on Monday, March 18, 2024, on 56 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
MACD Bearish Signal Line Cross Bearish 0.67%
Pocket Pivot Bullish Swing Setup 0.67%
Three Weeks Tight Range Contraction 0.67%
Wide Bands Range Expansion 0.67%
Overbought Stochastic Strength 0.67%
Wide Bands Range Expansion 2.75%
Overbought Stochastic Strength 2.75%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 9 hours ago
Up 1% about 9 hours ago
Rose Above Previous Day's High about 12 hours ago
60 Minute Opening Range Breakout about 12 hours ago
Fell Below 10 DMA about 13 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Natera, Inc. Description

Natera, Inc., a genetic testing company, develops and commercializes non-invasive methods for analyzing deoxyribonucleic acid (DNA) in the United States and Europe. The company primarily offers Panorama, a non-invasive prenatal test for fetal chromosomal abnormalities; Horizon test; and pre-implantation genetic screening and pre-implantation genetic diagnosis tests under the Spectrum brand to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization. It also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal DNA in a pregnant mother's blood and a blood sample from the alleged father; and high throughput carrier screening to determine the risk of passing severe genetic diseases on to offspring. Natera sells its tests directly and partner with other clinical laboratories to distribute its tests. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Clinical Medicine Acid Medical Genetics Medical Test In Vitro Lab Testing Genetic Diseases Applied Genetics DNA Genetic Testing In Vitro Fertilization DNA Paternity Testing Severe Genetic Diseases

Is NTRA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 93.48
52 Week Low 36.9
Average Volume 1,501,167
200-Day Moving Average 56.34
50-Day Moving Average 73.51
20-Day Moving Average 83.49
10-Day Moving Average 89.50
Average True Range 3.17
RSI (14) 69.33
ADX 46.43
+DI 30.37
-DI 10.91
Chandelier Exit (Long, 3 ATRs) 83.96
Chandelier Exit (Short, 3 ATRs) 77.55
Upper Bollinger Bands 99.82
Lower Bollinger Band 67.15
Percent B (%b) 0.7
BandWidth 39.14
MACD Line 5.33
MACD Signal Line 5.48
MACD Histogram -0.1449
Fundamentals Value
Market Cap 10.83 Billion
Num Shares 120 Million
EPS -4.51
Price-to-Earnings (P/E) Ratio -19.98
Price-to-Sales 8.55
Price-to-Book 10.68
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 93.57
Resistance 3 (R3) 93.48 92.24 93.00
Resistance 2 (R2) 92.24 91.36 92.29 92.80
Resistance 1 (R1) 91.18 90.82 91.71 91.27 92.61
Pivot Point 89.94 89.94 90.21 89.99 89.94
Support 1 (S1) 88.88 89.06 89.41 88.97 87.63
Support 2 (S2) 87.64 88.52 87.69 87.44
Support 3 (S3) 86.58 87.64 87.25
Support 4 (S4) 86.67